ESMO 2022: Adjuvant Atezolizumab for Patients With RCC at Increased Risk of Recurrence After Resection
Posted: 09/21/2022 | By: Sarah Campen, PharmD

The phase III IMmotion010 trial evaluated atezolizumab monotherapy vs placebo as adjuvant therapy in patients with renal cell carcinoma (RCC) who were at increased risk of recurrence after resection. Data from the trial was presented by Bex et al at the European Society for Medical Oncology (ESMO) Congress 2022 ( Abstract LBA6).

Question 1 of 5

What is the target of atezolizumab therapy?

Choose 1